Companies that have been working on treatments for coronavirus have been in focus among investors for quite a while and such stocks are from Relief Therapeutics (RLF.SW) (OTC: RLFTF).
After having slumped significantly in recent weeks, the Relief stock is now recovering and it could be a good idea for investors to look into some possible triggers. Last week there was an important development with regards to the company’s COVID 19 treatment RLF 100.
Relief and its partner NeuroRx announced the preliminary findings from the Phase 2b/3 trials of the product and the revelations were positive in nature. As per the data revealed from the trial, it was revealed that it could help in reducing the hospital stay for patients who suffer from respiratory problems arising out of COVID 19 infection.
The length of hospital stay was lower when compared against placebo. More importantly, the trials did not find any unexpected side effects either.